Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) hit a new 52-week low on Tuesday. The company traded as low as $11.81 and last traded at $11.8780, with a volume of 67,004 shares changing hands. The stock had previously closed at $12.45.
Analyst Ratings Changes
MESO has been the subject of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $39.00 price target (up from $35.00) on shares of Mesoblast in a research note on Thursday, August 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Thursday, September 24th. Finally, Weiss Ratings raised shares of Mesoblast from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $39.00.
Read Our Latest Report on MESO
Mesoblast Trading Down 4.7%
The company has a debt-to-equity ratio of 0.19, a current ratio of 2.43 and a quick ratio of 2.09. The company has a 50-day moving average price of $14.22 and a 200-day moving average price of $15.20.
Mesoblast (NASDAQ:MESO – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported ($0.07) EPS for the quarter. The company had revenue of $34.45 million during the quarter. On average, equities analysts anticipate that Mesoblast Limited will post -0.05 EPS for the current fiscal year.
Hedge Funds Weigh In On Mesoblast
A number of institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Mesoblast by 3.4% during the third quarter. Goldman Sachs Group Inc. now owns 409,192 shares of the company’s stock worth $5,995,000 after acquiring an additional 13,580 shares during the last quarter. Keel Point LLC acquired a new stake in shares of Mesoblast during the third quarter worth $2,553,000. Entropy Technologies LP purchased a new stake in shares of Mesoblast in the third quarter valued at $176,000. 49 Wealth Management LLC purchased a new stake in shares of Mesoblast in the third quarter valued at $268,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Mesoblast in the third quarter valued at $39,000. Institutional investors and hedge funds own 1.43% of the company’s stock.
Mesoblast Company Profile
Mesoblast is an Australia-based biotechnology company developing regenerative medicine products made from mesenchymal lineage cells. Its allogeneic cell therapies are designed to address inflammatory and immune-mediated conditions by modulating the body’s immune response and supporting tissue repair. The company’s lead commercial product, Ryoncil (remestemcel-L-rknd), is approved in the United States to treat steroid-refractory acute graft-versus-host disease in pediatric patients. A related product, marketed as Temcell in Japan, is used there to treat acute graft-versus-host disease.
Further Reading
- Five stocks we like better than Mesoblast
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
